<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-110655</identifier>
<setSpec>0213-9111</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Appropriateness of lipid-lowering treatment and cardiovascular risk in patients with hypercholesterolemia</dc:title>
<dc:description xml:lang="en">Objective: To assess the appropriateness of lipid-lowering treatment and to determine the clinical and epidemiological characteristics of patients with hypercholesterolemia. Method: The study population comprised all the patients diagnosed with hypercholesterolemia in three urban health centres. A sample of 724 patients was obtaind through a one-stage conglomerate method. A descriptive study was performed with two types of designs: retrospective and longitudinal, and cross-sectional. For the first we used the new Sheffield tables for cardiovascular risk; for the second, the Framingham categorical tables (Grundy). Results: Among patients in primary prevention, prescription of lipid-lowering therapy was appropiate in 44.2%. A total of 8.9% (SE = 1.1) of the patients aged 30-74 years in primary prevention had a high absolute risk (&amp;#8805; 20% over 10 years). Six percent (0.8) had a high relativd risk and 18.1% (2.0) had a moderately above-average risk. Conclusions: More than the half of the patients were prescribed lipid-lowering treatment that was not indicated by risk tables. The current cardiovascular risk of our patients is satisfactory (AU)</dc:description>
<dc:creator>Dosil Díaz, O</dc:creator>
<dc:creator>Segade Buceta,  X. M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Valorar la adecuación en la prescripción de hipolipemiantes y conocer diversas características clinicoepidemiológicas de los pacientes con hipercolesterolemia. Método: Población objeto de estudio: todos los pacientes con hipercolesterolemia pertenecientes a tres centros de salud urbanos. Muestreo por conglomerados monoetápico (n = 724). Estudio descriptivo con dos tipos de diseño: longitudinal retrospectivo y transversal. Para el primero de los diseños se utilizaron las nuevas tablas de riesgo cardiovascular (RCV) de Sheffield; para el segundo, las de Framingham por categorías (Grundy). Resultados: Entre los pacientes en prevención primaria, hubo una adecuación en la prescripción en un 44,2% de los pacientes. Tienen actualmente un riesgo absoluto elevado (&amp;#8805; 20% a 10 años) un 8,9% (1,1) de nuestros pacientes de 30 a 74 años de edad en  (..) (AU)</dc:description>
<dc:source>Gac Sanit;16(4): 318-323, jul.-ago. 2002. ilus, tab</dc:source>
<dc:identifier>ibc-110655</dc:identifier>
<dc:title xml:lang="es">Adecuación de la prescripción de hipolipemiantes y riesgocardiovascular en pacientes con hipercolesterolemia</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d11758^s22045</dc:subject>
<dc:subject>^d963^s22073</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d11742^s22083</dc:subject>
<dc:subject>^d7117^s22057</dc:subject>
<dc:subject>^d11756^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>200208</dc:date>
</metadata>
</record>
</ibecs-document>
